CASI Pharmaceuticals, Inc. (CASI)
USD 2.07
(-2.59%)
USD 2.07
(-2.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.15 Million USD | 109.08% |
| 2022 | -45.76 Million USD | -25.26% |
| 2021 | -36.53 Million USD | 34.49% |
| 2020 | -55.77 Million USD | -8.46% |
| 2019 | -51.42 Million USD | 37.83% |
| 2018 | -82.7 Million USD | -96.96% |
| 2017 | -41.99 Million USD | -64.02% |
| 2016 | -25.6 Million USD | -598.33% |
| 2015 | -3.66 Million USD | 60.49% |
| 2014 | -9.27 Million USD | 38.67% |
| 2013 | -15.13 Million USD | -90.35% |
| 2012 | -7.94 Million USD | -635.61% |
| 2011 | -1.08 Million USD | 73.83% |
| 2010 | -4.12 Million USD | -239.15% |
| 2009 | 2.96 Million USD | 139.4% |
| 2008 | -7.53 Million USD | 24.12% |
| 2007 | -9.92 Million USD | 50.73% |
| 2006 | -20.14 Million USD | -77.54% |
| 2005 | -11.34 Million USD | 44.45% |
| 2004 | -20.42 Million USD | 41.33% |
| 2003 | -34.81 Million USD | -81.29% |
| 2002 | -19.2 Million USD | 49.61% |
| 2001 | -38.1 Million USD | -69.36% |
| 2000 | -22.5 Million USD | 1.74% |
| 1999 | -22.9 Million USD | 25.65% |
| 1998 | -30.8 Million USD | -69.23% |
| 1997 | -18.2 Million USD | 44.85% |
| 1996 | -33 Million USD | -415.63% |
| 1995 | -6.4 Million USD | -3100.0% |
| 1994 | -200 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 8.93 Million USD | 39.89% |
| 2024 Q1 | 6.38 Million USD | 252.37% |
| 2023 Q1 | -16.59 Million USD | 63.75% |
| 2023 Q3 | -19.97 Million USD | -18.1% |
| 2023 FY | 4.15 Million USD | 109.08% |
| 2023 Q2 | -16.91 Million USD | -1.94% |
| 2023 Q4 | 1.81 Million USD | 109.07% |
| 2022 Q1 | -27.37 Million USD | 25.08% |
| 2022 Q3 | -22.18 Million USD | -38.97% |
| 2022 Q4 | -45.76 Million USD | -106.29% |
| 2022 Q2 | -15.96 Million USD | 41.68% |
| 2022 FY | -45.76 Million USD | -25.26% |
| 2021 FY | -36.53 Million USD | 34.49% |
| 2021 Q2 | -58.34 Million USD | 11.77% |
| 2021 Q3 | -52.04 Million USD | 10.8% |
| 2021 Q4 | -36.53 Million USD | 29.79% |
| 2021 Q1 | -66.12 Million USD | -18.56% |
| 2020 Q4 | -55.77 Million USD | 22.78% |
| 2020 Q1 | -53.18 Million USD | -3.42% |
| 2020 Q2 | -44.36 Million USD | 16.58% |
| 2020 Q3 | -72.22 Million USD | -62.8% |
| 2020 FY | -55.77 Million USD | -8.46% |
| 2019 Q3 | -61.94 Million USD | 6.1% |
| 2019 Q4 | -51.42 Million USD | 17.0% |
| 2019 Q1 | -98.23 Million USD | -18.78% |
| 2019 FY | -51.42 Million USD | 37.83% |
| 2019 Q2 | -65.97 Million USD | 32.84% |
| 2018 Q1 | -48.38 Million USD | -15.24% |
| 2018 Q3 | -97.36 Million USD | -50.45% |
| 2018 Q2 | -64.71 Million USD | -33.74% |
| 2018 Q4 | -82.7 Million USD | 15.06% |
| 2018 FY | -82.7 Million USD | -96.96% |
| 2017 Q2 | -21.86 Million USD | 9.03% |
| 2017 FY | -41.99 Million USD | -64.02% |
| 2017 Q4 | -41.99 Million USD | -108.46% |
| 2017 Q3 | -20.14 Million USD | 7.88% |
| 2017 Q1 | -24.03 Million USD | 6.12% |
| 2016 FY | -25.6 Million USD | -598.33% |
| 2016 Q4 | -25.6 Million USD | -13.02% |
| 2016 Q2 | -17.05 Million USD | -36.74% |
| 2016 Q3 | -22.65 Million USD | -32.81% |
| 2016 Q1 | -12.47 Million USD | -240.21% |
| 2015 Q3 | -4.96 Million USD | 23.82% |
| 2015 FY | -3.66 Million USD | 60.49% |
| 2015 Q4 | -3.66 Million USD | 26.17% |
| 2015 Q1 | -8.04 Million USD | 13.29% |
| 2015 Q2 | -6.51 Million USD | 18.99% |
| 2014 Q2 | -13.07 Million USD | 7.89% |
| 2014 Q4 | -9.27 Million USD | 11.2% |
| 2014 Q3 | -10.44 Million USD | 20.11% |
| 2014 FY | -9.27 Million USD | 38.67% |
| 2014 Q1 | -14.19 Million USD | 6.16% |
| 2013 FY | -15.13 Million USD | -90.35% |
| 2013 Q4 | -15.13 Million USD | 4.66% |
| 2013 Q3 | -15.87 Million USD | 7.85% |
| 2013 Q2 | -17.22 Million USD | 5.73% |
| 2013 Q1 | -18.27 Million USD | -129.84% |
| 2012 Q4 | -7.94 Million USD | 8.76% |
| 2012 Q2 | -10.05 Million USD | -245.84% |
| 2012 Q1 | -2.9 Million USD | -169.15% |
| 2012 FY | -7.94 Million USD | -635.61% |
| 2012 Q3 | -8.71 Million USD | 13.39% |
| 2011 FY | -1.08 Million USD | 73.83% |
| 2011 Q3 | -1.98 Million USD | 47.74% |
| 2011 Q1 | -4.8 Million USD | -16.28% |
| 2011 Q2 | -3.8 Million USD | 20.83% |
| 2011 Q4 | -1.08 Million USD | 45.59% |
| 2010 Q1 | -2.41 Million USD | -181.24% |
| 2010 FY | -4.12 Million USD | -239.15% |
| 2010 Q4 | -4.12 Million USD | 23.69% |
| 2010 Q3 | -5.4 Million USD | -89.46% |
| 2010 Q2 | -2.85 Million USD | -18.46% |
| 2009 Q4 | 2.96 Million USD | 149.09% |
| 2009 FY | 2.96 Million USD | 139.4% |
| 2009 Q1 | -5.14 Million USD | 31.73% |
| 2009 Q2 | -5.5 Million USD | -7.11% |
| 2009 Q3 | -6.04 Million USD | -9.76% |
| 2008 Q1 | 3.89 Million USD | 139.21% |
| 2008 FY | -7.53 Million USD | 24.12% |
| 2008 Q3 | 7.57 Million USD | 122.93% |
| 2008 Q2 | 3.39 Million USD | -12.74% |
| 2008 Q4 | -7.53 Million USD | -199.48% |
| 2007 Q4 | -9.92 Million USD | -4.91% |
| 2007 Q1 | -14.89 Million USD | 26.07% |
| 2007 Q3 | -9.46 Million USD | 13.59% |
| 2007 FY | -9.92 Million USD | 50.73% |
| 2007 Q2 | -10.94 Million USD | 26.49% |
| 2006 Q2 | -12.33 Million USD | 36.62% |
| 2006 FY | -20.14 Million USD | -77.54% |
| 2006 Q4 | -20.14 Million USD | 5.38% |
| 2006 Q3 | -21.28 Million USD | -72.55% |
| 2006 Q1 | -19.46 Million USD | -71.57% |
| 2005 Q1 | -21.06 Million USD | -3.15% |
| 2005 FY | -11.34 Million USD | 44.45% |
| 2005 Q4 | -11.34 Million USD | 38.23% |
| 2005 Q3 | -18.37 Million USD | -118.3% |
| 2005 Q2 | -8.41 Million USD | 60.06% |
| 2004 FY | -20.42 Million USD | 41.33% |
| 2004 Q3 | -8.3 Million USD | 38.79% |
| 2004 Q1 | -26.29 Million USD | 24.45% |
| 2004 Q2 | -13.56 Million USD | 48.42% |
| 2004 Q4 | -20.42 Million USD | -145.99% |
| 2003 Q2 | -17.82 Million USD | -175.03% |
| 2003 Q4 | -34.81 Million USD | -86.56% |
| 2003 Q3 | -18.65 Million USD | -4.7% |
| 2003 FY | -34.81 Million USD | -81.29% |
| 2003 Q1 | -6.47 Million USD | 66.25% |
| 2002 Q1 | -22.67 Million USD | 40.49% |
| 2002 Q2 | -6.8 Million USD | 70.0% |
| 2002 FY | -19.2 Million USD | 49.61% |
| 2002 Q3 | -417.92 Thousand USD | 93.86% |
| 2002 Q4 | -19.2 Million USD | -4494.66% |
| 2001 Q3 | -34.72 Million USD | -46.44% |
| 2001 Q1 | -37 Million USD | -64.44% |
| 2001 FY | -38.1 Million USD | -69.36% |
| 2001 Q4 | -38.1 Million USD | -9.73% |
| 2001 Q2 | -23.71 Million USD | 35.91% |
| 2000 Q1 | -26.64 Million USD | -16.35% |
| 2000 FY | -22.5 Million USD | 1.74% |
| 2000 Q3 | -35.75 Million USD | 24.86% |
| 2000 Q4 | -22.5 Million USD | 37.07% |
| 2000 Q2 | -47.58 Million USD | -78.61% |
| 1999 Q3 | -39.9 Million USD | -128.0% |
| 1999 Q4 | -22.9 Million USD | 42.61% |
| 1999 Q2 | -17.5 Million USD | 32.95% |
| 1999 Q1 | -26.1 Million USD | 15.26% |
| 1999 FY | -22.9 Million USD | 25.65% |
| 1998 Q4 | -30.8 Million USD | 10.47% |
| 1998 FY | -30.8 Million USD | -69.23% |
| 1998 Q1 | -26.5 Million USD | -45.6% |
| 1998 Q2 | -31.3 Million USD | -18.11% |
| 1998 Q3 | -34.4 Million USD | -9.9% |
| 1997 Q1 | -30.4 Million USD | 7.88% |
| 1997 Q2 | -29.4 Million USD | 3.29% |
| 1997 FY | -18.2 Million USD | 44.85% |
| 1997 Q3 | -25.9 Million USD | 11.9% |
| 1997 Q4 | -18.2 Million USD | 29.73% |
| 1996 Q4 | -33 Million USD | 37.97% |
| 1996 Q1 | -7.2 Million USD | -12.5% |
| 1996 FY | -33 Million USD | -415.63% |
| 1996 Q3 | -53.2 Million USD | 3.62% |
| 1996 Q2 | -55.2 Million USD | -666.67% |
| 1995 FY | -6.4 Million USD | -3100.0% |
| 1995 Q4 | -6.4 Million USD | 0.0% |
| 1994 FY | -200 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 107.429% |
| Alkermes plc | -166.73 Million USD | 102.493% |
| Agenus Inc. | 274.13 Million USD | 98.484% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 99.778% |
| Aptorum Group Limited | 1.35 Million USD | -206.253% |
| Ardelyx, Inc. | 34.51 Million USD | 87.958% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 2.897% |
| Bicycle Therapeutics plc | -481.46 Million USD | 100.863% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 88.508% |
| ChromaDex Corporation | -24.04 Million USD | 117.282% |
| Chimerix, Inc. | -25.51 Million USD | 116.287% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 40.357% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 117.553% |
| CRISPR Therapeutics AG | -150.84 Million USD | 102.755% |
| Precision BioSciences, Inc. | -85.41 Million USD | 104.866% |
| Dyadic International, Inc. | -6.37 Million USD | 165.16% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 126.084% |
| Fortress Biotech, Inc. | 7.66 Million USD | 45.78% |
| Lantern Pharma Inc. | -21.7 Million USD | 119.149% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 103.76% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 148.647% |
| Incyte Corporation | -3.17 Billion USD | 100.131% |
| IO Biotech, Inc. | -140.69 Million USD | 102.954% |
| Jaguar Health, Inc. | 29.39 Million USD | 85.86% |
| Novavax, Inc. | -298.29 Million USD | 101.393% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 22.129% |
| Opthea Limited | 28.15 Million USD | 85.24% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 124.754% |
| ContextLogic Inc. | -232 Million USD | 101.791% |
| MiMedx Group, Inc. | -33.9 Million USD | 112.259% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 59.235% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 279.368% |
| NextCure, Inc. | -6.47 Million USD | 164.166% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 108.23% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 165.151% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 65.832% |
| Vaxcyte, Inc. | -368.22 Million USD | 101.129% |
| PDS Biotechnology Corporation | -32.7 Million USD | 112.706% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 75.946% |
| Pharming Group N.V. | 109.8 Million USD | 96.215% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 123.891% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 102.372% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 122.441% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 122.441% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 158.535% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 170.922% |
| Acelyrin, Inc. | -216.9 Million USD | 101.916% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 174.078% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 341.067% |
| Summit Therapeutics Inc. | 34.67 Million USD | 88.014% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 161.091% |
| Senti Biosciences, Inc. | 1.74 Million USD | -138.851% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 102.251% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 105.366% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 168.558% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -4065.623% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -561.783% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 103.551% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 102.47% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 96.251% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 154.713% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 103.219% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 39.721% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 101.715% |
| Immix Biopharma, Inc. | -17.5 Million USD | 123.735% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 101.312% |
| MEI Pharma, Inc. | -3.7 Million USD | 212.173% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 66.781% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 97.43% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 85.047% |
| Fortress Biotech, Inc. | 7.66 Million USD | 45.78% |
| Precigen, Inc. | -481 Thousand USD | 964.033% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 70.485% |
| AlloVir, Inc. | -62.69 Million USD | 106.629% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 107.473% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 93.26% |
| ImmuCell Corporation | 10.99 Million USD | 62.186% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 102.696% |
| Onconetix, Inc. | 5.33 Million USD | 22.047% |
| PureTech Health plc | -167.19 Million USD | 102.486% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 113.644% |
| Elevation Oncology, Inc. | -19.11 Million USD | 121.739% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 184.661% |
| Seer, Inc. | -4.24 Million USD | 198.019% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 117.29% |
| Innoviva, Inc. | 255.56 Million USD | 98.374% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 107.439% |
| ESSA Pharma Inc. | -33.62 Million USD | 112.361% |
| GlycoMimetics, Inc. | -40.98 Million USD | 110.14% |
| GT Biopharma, Inc. | -1.02 Million USD | 507.052% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 106.131% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 93.215% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 103.1% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 129.994% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 114.395% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 5616.765% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 113.466% |
| Aptose Biosciences Inc. | -8.19 Million USD | 150.715% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 232.821% |
| Soligenix, Inc. | -4.95 Million USD | 183.933% |
| Century Therapeutics, Inc. | 847 Thousand USD | -390.673% |
| Kura Oncology, Inc. | -20.11 Million USD | 120.658% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 110.155% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 149.488% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -128.139% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 229.997% |
| Autolus Therapeutics plc | -186.59 Million USD | 102.227% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 108.429% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 101.507% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 87.872% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 97.472% |
| GRI Bio, Inc. | -1.79 Million USD | 331.661% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 146.265% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 112.497% |
| IGM Biosciences, Inc. | -72.6 Million USD | 105.724% |
| INmune Bio, Inc. | -25.41 Million USD | 116.355% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 97.247% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 108.204% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 125.576% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 244.059% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 89.067% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 110.091% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 86.966% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 98.9% |
| Verastem, Inc. | -37.27 Million USD | 111.149% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 145.806% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 108.014% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 127.46% |
| Histogen Inc. | -7.48 Million USD | 155.51% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 119.235% |
| Surrozen, Inc. | -32.66 Million USD | 112.723% |
| Organovo Holdings, Inc. | -1.5 Million USD | 375.78% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 198.87% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 78.08% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -58.869% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 149.587% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 109.567% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 128.511% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 101.312% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 675.575% |
| Apollomics, Inc. | -27.39 Million USD | 115.171% |
| Amarin Corporation plc | -191.04 Million USD | 102.175% |
| Mesoblast Limited | 55.96 Million USD | 92.574% |
| Turnstone Biologics Corp. | -14.58 Million USD | 128.497% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 116.432% |
| Synaptogenix, Inc. | -28.66 Million USD | 114.5% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 544.017% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 91.472% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 582.085% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 157.197% |
| Exelixis, Inc. | -73.05 Million USD | 105.689% |
| Better Therapeutics, Inc. | -860 Thousand USD | 583.256% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 117.307% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 101.722% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -464.623% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 155.874% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -231.419% |
| Gritstone bio, Inc. | 39.49 Million USD | 89.476% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 104.942% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 257.894% |
| Avid Bioservices, Inc. | 169.72 Million USD | 97.551% |
| Insmed Incorporated | 721.62 Million USD | 99.424% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 145.463% |
| MediWound Ltd. | -5.32 Million USD | 178.091% |
| OmniAb, Inc. | 9.2 Million USD | 54.841% |
| Alector, Inc. | -35.63 Million USD | 111.662% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 95.166% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 184.334% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 68.608% |
| Zai Lab Limited | -775 Million USD | 100.536% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 98.78% |
| Aura Biosciences, Inc. | -21.52 Million USD | 119.308% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 105.039% |
| Immunic, Inc. | -45.34 Million USD | 109.166% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 102.151% |
| Veracyte, Inc. | -203.82 Million USD | 102.039% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 99.349% |
| FibroGen, Inc. | 56.76 Million USD | 92.679% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 53.33% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 247.007% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 300.739% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 99.909% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 224.394% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 102.504% |
| TG Therapeutics, Inc. | 17.86 Million USD | 76.733% |
| Galecto, Inc. | -21.21 Million USD | 119.589% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 117.473% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 99.735% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 116.983% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 136.117% |
| XBiotech Inc. | -200.02 Million USD | 102.078% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 104.942% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 8.216% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 111.786% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 105.382% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 26.972% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 102.439% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 104.499% |
| Vaxxinity, Inc. | 10.13 Million USD | 58.981% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 99.436% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 138.597% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 106.301% |
| NexImmune, Inc. | -3.13 Million USD | 232.625% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 220.371% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 127.502% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 115.336% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 146.301% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 3436.143% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 110.244% |
| Ainos, Inc. | 4.07 Million USD | -1.915% |
| Pluri Inc. | 22.82 Million USD | 81.795% |
| Prothena Corporation plc | -608.34 Million USD | 100.683% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 103.5% |
| Celularity Inc. | 65.19 Million USD | 93.625% |
| Rallybio Corporation | -24.1 Million USD | 117.243% |
| Cue Biopharma, Inc. | -33.81 Million USD | 112.289% |
| MeiraGTx Holdings plc | -40.3 Million USD | 110.312% |
| Omeros Corporation | 331.17 Million USD | 98.745% |
| Humacyte, Inc. | -22.48 Million USD | 118.483% |
| Immunocore Holdings plc | -358.59 Million USD | 101.159% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 116.911% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 113.449% |
| Blueprint Medicines Corporation | 702.83 Million USD | 99.409% |
| CalciMedica, Inc. | -5.53 Million USD | 175.154% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 102.208% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 140.689% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 110.38% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 112.498% |
| Pulmatrix, Inc. | -10.41 Million USD | 139.896% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 169.533% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 110.896% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 103.731% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 106.933% |
| Cytokinetics, Incorporated | 642.37 Million USD | 99.353% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 171.372% |
| Nutriband Inc. | -251.65 Thousand USD | 1751.454% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 112.181% |
| Vor Biopharma Inc. | 4.3 Million USD | 3.349% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.069% |
| Evogene Ltd. | -19.63 Million USD | 121.167% |
| ProKidney Corp. | -56.23 Million USD | 107.39% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 108.539% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 144.992% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 99.695% |
| CorMedix Inc. | -43.05 Million USD | 109.653% |
| BioLineRx Ltd. | 7.33 Million USD | 43.348% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 115.132% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 90.994% |
| Atai Life Sciences N.V. | -28.55 Million USD | 114.553% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -86.324% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 118.215% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 76.566% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 105.536% |
| MediciNova, Inc. | -50.78 Million USD | 108.184% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 105.274% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 18575.217% |
| GeoVax Labs, Inc. | -6.45 Million USD | 164.408% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 102.08% |
| Biomea Fusion, Inc. | -166.57 Million USD | 102.495% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 102.322% |
| Mereo BioPharma Group plc | -51.46 Million USD | 108.075% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 104.382% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 101.415% |
| Absci Corporation | -72.59 Million USD | 105.725% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 8.979% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 101.773% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 104.411% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 104.343% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 110.637% |
| Allakos Inc. | -24.97 Million USD | 116.641% |
| Imunon, Inc. | -4.21 Million USD | 198.627% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 128.192% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 103.069% |
| BioAtla, Inc. | -109.01 Million USD | 103.812% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -464.623% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 542.599% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 65.268% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 119.601% |
| XOMA Corporation | -29 Million USD | 114.331% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 125.097% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 146.096% |
| aTyr Pharma, Inc. | -7.44 Million USD | 155.793% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 103.335% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 101.997% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 105.082% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 104.48% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 583.715% |
| Akari Therapeutics, Plc | -3.84 Million USD | 208.088% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -156.086% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 99.699% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 449.792% |
| UroGen Pharma Ltd. | 4.39 Million USD | 5.352% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 96.338% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -5675.27% |
| Orgenesis Inc. | 21.78 Million USD | 80.922% |
| Entera Bio Ltd. | -10.62 Million USD | 139.101% |
| GH Research PLC | -78.07 Million USD | 105.323% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 118.647% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 115.589% |
| Xencor, Inc. | 29.64 Million USD | 85.98% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 310.985% |
| Replimune Group, Inc. | 1.41 Million USD | -194.334% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 1796.964% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 103.288% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 449.792% |
| Portage Biotech Inc. | -4.98 Million USD | 183.437% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 18575.217% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 106.285% |
| OncoCyte Corporation | -6.56 Million USD | 163.325% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -363.109% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 191.228% |
| Purple Biotech Ltd. | -14.13 Million USD | 129.396% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 117.495% |
| scPharmaceuticals Inc. | -6.54 Million USD | 163.499% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 124.898% |
| HilleVax, Inc. | -165.48 Million USD | 102.511% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 263.751% |
| Tharimmune, Inc. | -10.93 Million USD | 138.005% |
| Genprex, Inc. | -6.73 Million USD | 161.683% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 101.127% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 104.698% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 396.645% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 225.296% |
| OKYO Pharma Limited | -826.84 Thousand USD | 602.632% |
| Savara Inc. | 153 Thousand USD | -2616.34% |
| Curis, Inc. | -23.88 Million USD | 117.399% |
| Daré Bioscience, Inc. | -5.15 Million USD | 180.575% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 635.559% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 166.946% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -250.717% |
| BeiGene, Ltd. | -2.25 Billion USD | 100.184% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 66.317% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 100.683% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 102.239% |
| Erasca, Inc. | -37.21 Million USD | 111.167% |
| bluebird bio, Inc. | 108.57 Million USD | 96.172% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 422.698% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 98.903% |
| DBV Technologies S.A. | -126.98 Million USD | 103.273% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 422.698% |
| Moderna, Inc. | -2.9 Billion USD | 100.143% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 140.147% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 138.241% |
| Molecular Templates, Inc. | 707 Thousand USD | -487.836% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 113.248% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 98.801% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 105.064% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 104.531% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 112.878% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 112.09% |
| MacroGenics, Inc. | -66.98 Million USD | 106.204% |
| RenovoRx, Inc. | -1.17 Million USD | 454.305% |
| Adicet Bio, Inc. | -138.78 Million USD | 102.995% |
| Prime Medicine, Inc. | -27.94 Million USD | 114.874% |
| Aditxt, Inc. | 18.12 Million USD | 77.065% |
| Adagene Inc. | -87.62 Million USD | 104.743% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 199.774% |
| Quantum-Si incorporated | -118.55 Million USD | 103.505% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 88.457% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 155.605% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 108.567% |
| SciSparc Ltd. | -2.06 Million USD | 301.259% |
| Vericel Corporation | 1.27 Million USD | -225.45% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 134.657% |
| Minerva Neurosciences, Inc. | 41 Million USD | 89.864% |
| Generation Bio Co. | 31.44 Million USD | 86.785% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 102.37% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 113.44% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 96.435% |
| Invivyd, Inc. | -198.47 Million USD | 102.094% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 104.604% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 273.334% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 105.871% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 160.894% |
| 2seventy bio, Inc. | 181.71 Million USD | 97.713% |
| ADMA Biologics, Inc. | 90.06 Million USD | 95.386% |
| Clene Inc. | 3.34 Million USD | -24.431% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 145.757% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 119.32% |
| GeoVax Labs, Inc. | -6.45 Million USD | 164.408% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 101.208% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 115.985% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 97.661% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 201.575% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 16.913% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 179.785% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 103.189% |
| Evaxion Biotech A/S | 5.28 Million USD | 21.39% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 103.692% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 103.166% |
| Trevena, Inc. | 2.25 Million USD | -84.057% |
| Surrozen, Inc. | -32.66 Million USD | 112.723% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 108.068% |
| Cingulate Inc. | 3.08 Million USD | -34.818% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 241.505% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 42.173% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 144.73% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 105.239% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 103.162% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 103.938% |
| Clearmind Medicine Inc. | -3.94 Million USD | 205.412% |
| Kronos Bio, Inc. | -36.05 Million USD | 111.527% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 55.83% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -185.023% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 107.66% |
| Statera Biopharma, Inc. | 14.41 Million USD | 71.172% |
| ImmunityBio, Inc. | 618.22 Million USD | 99.328% |
| Korro Bio, Inc. | -132.94 Million USD | 103.126% |
| Kineta, Inc. | -4.54 Million USD | 191.522% |
| BioVie Inc. | -17.73 Million USD | 123.437% |
| Codexis, Inc. | -43.27 Million USD | 109.605% |
| Celularity Inc. | 65.19 Million USD | 93.625% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 231.145% |
| Celcuity Inc. | 6.78 Million USD | 38.734% |
| Virax Biolabs Group Limited | -3.36 Million USD | 223.509% |
| Cibus, Inc. | -8.07 Million USD | 151.448% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 198.274% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 9.059% |
| IN8bio, Inc. | -16.38 Million USD | 125.358% |
| Kodiak Sciences Inc. | -103.87 Million USD | 104.001% |
| Annexon, Inc. | -193.75 Million USD | 102.145% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -11444.444% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 123.75% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 218.303% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 99.606% |
| Eyenovia, Inc. | 1.25 Million USD | -230.181% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 84.553% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 228.153% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 112.5% |
| Arcellx, Inc. | -296.95 Million USD | 101.4% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 121.306% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 107.059% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 120.051% |
| Moolec Science SA | 117.61 Thousand USD | -3433.533% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 110.823% |
| Geron Corporation | 14.76 Million USD | 71.845% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 110.96% |
| Royalty Pharma plc | 5.65 Billion USD | 99.927% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 102.939% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 159.461% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 177.496% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 102.953% |
| Humacyte, Inc. | -22.48 Million USD | 118.483% |
| Structure Therapeutics Inc. | -124.33 Million USD | 103.342% |
| 89bio, Inc. | -289.05 Million USD | 101.438% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 116.465% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 333.09% |
| Genelux Corporation | -6.89 Million USD | 160.241% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 113.381% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 95.029% |
| Notable Labs, Ltd. | -9.77 Million USD | 142.512% |
| Liquidia Corporation | -80.17 Million USD | 105.184% |
| Mustang Bio, Inc. | -3.73 Million USD | 211.242% |
| Immunovant, Inc. | -635.22 Million USD | 100.654% |
| Quantum-Si incorporated | -118.55 Million USD | 103.505% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 123.662% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 200.314% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 48.225% |
| Acasti Pharma Inc. | -23 Million USD | 118.066% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 223.425% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 125.576% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 103.017% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 233.361% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 118.694% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 122.381% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 102.455% |
| PepGen Inc. | -60.67 Million USD | 106.85% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 118.088% |
| United Therapeutics Corporation | -507.7 Million USD | 100.819% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 121.73% |
| Solid Biosciences Inc. | -47.75 Million USD | 108.704% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 582.085% |
| Immuneering Corporation | -54.94 Million USD | 107.564% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 198.87% |
| Silo Pharma, Inc. | -3.52 Million USD | 217.924% |
| Belite Bio, Inc | -87.27 Million USD | 104.762% |
| XOMA Corporation | -29 Million USD | 114.331% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 105.879% |
| Bionomics Limited | 227 Million USD | 98.169% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 103.574% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 264.074% |
| uniQure N.V. | -102.95 Million USD | 104.037% |
| Cassava Sciences, Inc. | -121.13 Million USD | 103.431% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 199.774% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 89.851% |
| Forte Biosciences, Inc. | -11.96 Million USD | 134.746% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 234.316% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -3820.755% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 228.153% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 53.33% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 156.041% |
| Altimmune, Inc. | -134.48 Million USD | 103.09% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 97.902% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 264.074% |
| Compugen Ltd. | -12.9 Million USD | 132.207% |
| Peak Bio, Inc. | 10.34 Million USD | 59.807% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 1568.551% |
| Benitec Biopharma Inc. | -50.58 Million USD | 108.216% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 103.983% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 78.844% |
| Zura Bio Limited | -99.8 Million USD | 104.164% |
| PolyPid Ltd. | 6.17 Million USD | 32.642% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 94.393% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 78.844% |
| Instil Bio, Inc. | 75.35 Million USD | 94.485% |
| argenx SE | -2.02 Billion USD | 100.205% |
| Immunome, Inc. | -97.02 Million USD | 104.283% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 118.475% |
| Verona Pharma plc | -220.44 Million USD | 101.885% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 105.793% |
| Shattuck Labs, Inc. | -121.42 Million USD | 103.423% |
| CervoMed Inc. | -7.79 Million USD | 153.331% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 102.24% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 195.038% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 103.155% |
| Moolec Science SA | 117.61 Thousand USD | -3433.533% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 281.645% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 73.859% |
| AnaptysBio, Inc. | -18.15 Million USD | 122.897% |
| Design Therapeutics, Inc. | -18.15 Million USD | 122.898% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 105.905% |
| NeurAxis, Inc. | 145.7 Thousand USD | -2752.437% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 62.999% |
| Lumos Pharma, Inc. | -28.49 Million USD | 114.586% |
| Achilles Therapeutics plc | -126.92 Million USD | 103.274% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 105.793% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 733.797% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 120.006% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -185.023% |
| Nutriband Inc. | -251.65 Thousand USD | 1751.454% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 131.554% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 155.86% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 98.778% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 82.49% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 100.929% |
| Palisade Bio, Inc. | -12.06 Million USD | 134.452% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 102.962% |
| Beam Therapeutics Inc. | -262.72 Million USD | 101.582% |
| Neurogene Inc. | -131.95 Million USD | 103.15% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 80.95% |
| AEON Biopharma, Inc. | -4.88 Million USD | 185.164% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 101.102% |
| Sesen Bio, Inc. | -112.55 Million USD | 103.692% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 104.162% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 277.017% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 110.649% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 104.99% |
| Athira Pharma, Inc. | -88.99 Million USD | 104.67% |
| Vaccinex, Inc. | -1.28 Million USD | 422.671% |
| HCW Biologics Inc. | 2.85 Million USD | -45.484% |
| XOMA Corporation | -29 Million USD | 114.331% |
| Nektar Therapeutics | 210.24 Million USD | 98.023% |
| Arvinas, Inc. | -313.8 Million USD | 101.324% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -156.086% |
| Merus N.V. | -192.88 Million USD | 102.155% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 93.072% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 159.902% |
| Rezolute, Inc. | -68.16 Million USD | 106.097% |
| Clene Inc. | 3.34 Million USD | -24.431% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 131.516% |
| BeyondSpring Inc. | -13.75 Million USD | 130.214% |
| Synlogic, Inc. | -6.68 Million USD | 162.169% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -266.49% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 149.154% |
| Peak Bio, Inc. | 10.34 Million USD | 59.807% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 105.042% |
| Krystal Biotech, Inc. | -350.23 Million USD | 101.187% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 96.652% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 102.459% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 231.638% |
| MannKind Corporation | 143.89 Million USD | 97.112% |
| Ikena Oncology, Inc. | -109.15 Million USD | 103.807% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 154.894% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 112.556% |
| Gossamer Bio, Inc. | 180.35 Million USD | 97.696% |
| CohBar, Inc. | -5.93 Million USD | 170.076% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 113.971% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 8.979% |
| Legend Biotech Corporation | -949.39 Million USD | 100.438% |
| Mural Oncology plc | -255.84 Million USD | 101.624% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 87.099% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 188.226% |
| Disc Medicine, Inc. | -358.28 Million USD | 101.16% |
| Champions Oncology, Inc. | 4.81 Million USD | 13.633% |
| REGENXBIO Inc. | 54.76 Million USD | 92.412% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 1645.516% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 102.752% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 146.116% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 105.151% |
| Vaxart, Inc. | -8.24 Million USD | 150.431% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 108.282% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 103.268% |
| Cellectis S.A. | -43.85 Million USD | 109.477% |
| Longeveron Inc. | -2.9 Million USD | 242.916% |
| Repare Therapeutics Inc. | -107.85 Million USD | 103.853% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 99.571% |
| Inozyme Pharma, Inc. | 12 Million USD | 65.378% |
| Revolution Medicines, Inc. | -608.2 Million USD | 100.683% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 437.886% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 101.568% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 102.769% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 126.561% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 661.622% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.043% |
| Denali Therapeutics Inc. | -74.86 Million USD | 105.551% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 134.657% |
| Veru Inc. | 4.77 Million USD | 13.054% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 136.955% |
| Cingulate Inc. | 3.08 Million USD | -34.818% |
| Passage Bio, Inc. | 4.58 Million USD | 9.357% |
| Context Therapeutics Inc. | -14.44 Million USD | 128.762% |
| Exicure, Inc. | 5.84 Million USD | 28.945% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 101.804% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 110.503% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 73.513% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 107.066% |
| Nuvalent, Inc. | -335.38 Million USD | 101.239% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -139.63% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 105.58% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 146.749% |
| OmniAb, Inc. | 9.2 Million USD | 54.841% |
| Anew Medical, Inc. | 1.43 Million USD | -190.129% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 74.63% |
| Lipocine Inc. | -4.75 Million USD | 187.41% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 103.784% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 72.714% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 108.204% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 83.304% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 161.836% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 106.314% |
| Ocugen, Inc. | -32.52 Million USD | 112.779% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 104.857% |
| Q32 Bio Inc. | -37.94 Million USD | 110.952% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 761.783% |
| Alumis Inc. Common Stock | -13.52 Million USD | 130.719% |
| Equillium, Inc. | -22.39 Million USD | 118.56% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 116.255% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 112.738% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 1776.381% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 96.899% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -29.956% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -1165.372% |
| Dominari Holdings Inc. | 195 Thousand USD | -2031.282% |
| Edesa Biotech, Inc. | -5.26 Million USD | 178.908% |
| vTv Therapeutics Inc. | -8.91 Million USD | 146.608% |
| Bio-Techne Corporation | 267.74 Million USD | 98.448% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 125.64% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 103.519% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 149.459% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 132.851% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 101.696% |
| Nkarta, Inc. | 57.29 Million USD | 92.747% |
| BioCardia, Inc. | 212 Thousand USD | -1860.377% |
| Iterum Therapeutics plc | 13.43 Million USD | 69.073% |